{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:55:50Z","timestamp":1778252150251,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company, Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"DOI":"10.1186\/s40842-025-00260-6","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T23:01:55Z","timestamp":1766098915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of tofogliflozin on cardiac sympathetic nerve activity in type 2 diabetes mellitus patients with heart failure (TARGET-HF): rationale and design of the single-arm intervention trial"],"prefix":"10.1186","volume":"11","author":[{"given":"Takahiro","family":"Okumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko K","family":"Bando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fusako","family":"Sera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Hiraiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"260_CR1","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1253\/circj.CJ-20-1154","volume":"85","author":"W Fujimoto","year":"2021","unstructured":"Fujimoto W, Toh R, Takegami M, Hayashi T, Kuroda K, Hatani Y, et al. Estimating incidence of acute heart failure syndromes in Japan\u2014An analysis from the KUNIUMI registry. Circ J. 2021;85:1860\u20138. https:\/\/doi.org\/10.1253\/circj.CJ-20-1154.","journal-title":"Circ J"},{"key":"260_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1592\/phco.28.2.170","volume":"28","author":"CK Choy","year":"2008","unstructured":"Choy CK, Rodgers JE, Nappi JM, Haines ST. Type 2 diabetes mellitus and heart failure. Pharmacotherapy. 2008;28:170\u201392. https:\/\/doi.org\/10.1592\/phco.28.2.170.","journal-title":"Pharmacotherapy"},{"key":"260_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.diabres.2011.02.023","volume":"92","author":"M Sakakibara","year":"2011","unstructured":"Sakakibara M, Hirashiki A, Cheng XW, Bando Y, Ohshima K, Okumura T, et al. Association of diabetes mellitus with myocardial collagen accumulation and relaxation impairment in patients with dilated cardiomyopathy. Diabetes Res Clin Pract. 2011;92:348\u201355. https:\/\/doi.org\/10.1016\/j.diabres.2011.02.023.","journal-title":"Diabetes Res Clin Pract"},{"key":"260_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"260_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"key":"260_CR6","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-25-0002","author":"T Kitai","year":"2025","unstructured":"Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, et al. JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. Circ J. 2025. https:\/\/doi.org\/10.1253\/circj.CJ-25-0002. [Epub ahead of print].","journal-title":"Circ J"},{"key":"260_CR7","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"key":"260_CR8","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"key":"260_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","volume":"2","author":"S Verma","year":"2017","unstructured":"Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol. 2017;2:939\u201340. https:\/\/doi.org\/10.1001\/jamacardio.2017.1891.","journal-title":"JAMA Cardiol"},{"key":"260_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/eurheartjsupp\/suac030","volume":"24","author":"E Gronda","year":"2022","unstructured":"Gronda E, Dusi V, D\u2019Elia E, Iacoviello M, Benvenuto E, Vanoli E. Sympathetic activation in heart failure. Eur Heart J Suppl. 2022;24:Suppl E:E4\u2013E11. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac030.","journal-title":"Eur Heart J Suppl"},{"key":"260_CR11","first-page":"217","volume":"40","author":"T Toyama","year":"1999","unstructured":"Toyama T, Aihara Y, Iwasaki T, Hasegawa A, Suzuki T, Nagai R, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after \u03b2-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med. 1999;40:217\u201323.","journal-title":"J Nucl Med"},{"key":"260_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jcmg.2013.02.007","volume":"6","author":"T Nakata","year":"2013","unstructured":"Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6:772\u201384. https:\/\/doi.org\/10.1016\/j.jcmg.2013.02.007.","journal-title":"JACC Cardiovasc Imaging"},{"key":"260_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00259-007-0639-3","volume":"35","author":"D Agostini","year":"2008","unstructured":"Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535\u201346. https:\/\/doi.org\/10.1007\/s00259-007-0639-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"260_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.17996\/anc.23-00003","volume":"9","author":"S Yamashita","year":"2023","unstructured":"Yamashita S, Nakajima K, Okuda K, Yamamoto H, Shibutani T, Yoneyama T, et al. Phantom-based standardization method for 123I-metaiodobenzylguanidine heart-to-mediastinum ratio validated by D-SPECT versus Anger camera. Ann Nucl Cardiol. 2023;9:85\u201390. https:\/\/doi.org\/10.17996\/anc.23-00003.","journal-title":"Ann Nucl Cardiol"},{"key":"260_CR15","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/ehjci\/jev322","volume":"17","author":"K Nakajima","year":"2016","unstructured":"Nakajima K, Nakata T, Matsuo S, Jacobson AF. Creation of mortality risk charts using 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models. Eur Heart J Cardiovasc Imaging. 2016;17:1138\u201345. https:\/\/doi.org\/10.1093\/ehjci\/jev322.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"260_CR16","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.jacc.2010.01.014","volume":"55","author":"AF Jacobson","year":"2010","unstructured":"Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart Failure) study. J Am Coll Cardiol. 2010;55:2212\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2010.01.014.","journal-title":"J Am Coll Cardiol"},{"key":"260_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1253\/circj.CJ-15-0952","volume":"80","author":"S Matsuo","year":"2016","unstructured":"Matsuo S, Nakajima K, Nakata T. Prognostic value of cardiac sympathetic nerve imaging using Long-Term Follow-up Data\u2014Ischemic vs. non-ischemic heart failure etiology. Circ J. 2016;80:435\u201341. https:\/\/doi.org\/10.1253\/circj.CJ-15-0952.","journal-title":"Circ J"},{"key":"260_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00259-008-0971-2","volume":"36","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Nakajima K, Okuda K, Kawano M, Ishikawa T, Hosoya T, et al. Standardization of the heart-to-mediastinum ratio of 123I-labelled-metaiodobenzylguanidine uptake using the dual energy window method: feasibility of correction with different camera-collimator combinations. Eur J Nucl Med Mol Imaging. 2009;36:560\u20136. https:\/\/doi.org\/10.1007\/s00259-008-0971-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"260_CR19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s12350-014-9916-2","volume":"21","author":"K Nakajima","year":"2014","unstructured":"Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 Metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21:970\u20138. https:\/\/doi.org\/10.1007\/s12350-014-9916-2.","journal-title":"J Nucl Cardiol"},{"key":"260_CR20","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"260_CR21","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. Diabetologia. 2018;61:2108\u201317. https:\/\/doi.org\/10.1007\/s00125-018-4670-7.","journal-title":"Diabetologia"},{"key":"260_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5582\/ddt.2017.01069","volume":"12","author":"S Kiuchi","year":"2018","unstructured":"Kiuchi S, Hisatake S, Kabuki T, Fujii T, Oka T, Dobashi S, et al. Long-term use of Ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report. Drug Discov Ther. 2018;12:51\u20134. https:\/\/doi.org\/10.5582\/ddt.2017.01069.","journal-title":"Drug Discov Ther"},{"key":"260_CR23","doi-asserted-by":"publisher","first-page":"155243","DOI":"10.1016\/j.metabol.2022.155243","volume":"137","author":"C Sardu","year":"2022","unstructured":"Sardu C, Massimo Massetti M, Rambaldi P, Gatta G, Cappabianca S, Sasso FC, et al. SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study. Metabolism. 2022;137:155243. https:\/\/doi.org\/10.1016\/j.metabol.2022.155243.","journal-title":"Metabolism"},{"key":"260_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","volume":"19","author":"W Shimizu","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020;19:148. https:\/\/doi.org\/10.1186\/s12933-020-01127-z.","journal-title":"Cardiovasc Diabetol"},{"key":"260_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","volume":"21","author":"Y Suzuki","year":"2022","unstructured":"Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, et al. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Cardiovasc Diabetol. 2022;21:67. https:\/\/doi.org\/10.1186\/s12933-022-01508-6.","journal-title":"Cardiovasc Diabetol"},{"key":"260_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10557-019-06892-y","volume":"33","author":"M Otagaki","year":"2019","unstructured":"Otagaki M, Matsumura K, Kin H, Fujii K, Shibutani H, Matsumoto H, et al. Effect of Tofogliflozin on systolic and diastolic cardiac function in type 2 diabetic patients. Cardiovasc Drugs Ther. 2019;33:435\u201342. https:\/\/doi.org\/10.1007\/s10557-019-06892-y.","journal-title":"Cardiovasc Drugs Ther"},{"key":"260_CR27","doi-asserted-by":"publisher","first-page":"177595","DOI":"10.1016\/j.ejphar.2025.177595","volume":"996","author":"W Zhuang","year":"2025","unstructured":"Zhuang W, Park M, Jeong J, Kim HR, Jang Y, Seo MS, et al. The sodium-glucose cotransporter 2 inhibitor tofogliflozin induces vasodilation of rabbit femoral artery by activating Kv channels, the SERCA pump, and the sGC\/cGMP pathway. Eur J Pharmacol. 2025;996:177595. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177595.","journal-title":"Eur J Pharmacol"},{"key":"260_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jjcc.2017.02.005","volume":"70","author":"R Morimoto","year":"2017","unstructured":"Morimoto R, Okumura T, Hirashiki A, Ishii H, Ichii T, Aoki S, et al. Myocardial contractile reserve predicts left ventricular reverse remodeling and cardiac events in dilated cardiomyopathy. J Cardiol. 2017;70:303\u20139. https:\/\/doi.org\/10.1016\/j.jjcc.2017.02.005.","journal-title":"J Cardiol"},{"key":"260_CR29","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.jacc.2005.08.046","volume":"46","author":"S Ohshima","year":"2005","unstructured":"Ohshima S, Isobe S, Izawa H, Nanasato M, Ando A, Yamada A, et al. Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathy patients. J Am Coll Cardiol. 2005;46:2061\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2005.08.046.","journal-title":"J Am Coll Cardiol"},{"key":"260_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1161\/01.CIR.0000081775.72651.B6","volume":"108","author":"MP Schlaich","year":"2003","unstructured":"Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560\u20135. https:\/\/doi.org\/10.1161\/01.CIR.0000081775.72651.B6.","journal-title":"Circulation"},{"key":"260_CR31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1161\/HYPERTENSIONAHA.111.00612","volume":"61","author":"JR Sowers","year":"2013","unstructured":"Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013;61:943\u20137. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.00612.","journal-title":"Hypertension"},{"key":"260_CR32","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","volume":"35","author":"VB Matthews","year":"2017","unstructured":"Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017;35:2059\u201368. https:\/\/doi.org\/10.1097\/HJH.0000000000001434.","journal-title":"J Hypertens"},{"key":"260_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","volume":"5","author":"LY Herat","year":"2020","unstructured":"Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, et al. SGLT2 inhibitor-induced sympathoinhibition: A novel mechanism for cardiorenal protection. JACC Basic Transl Sci. 2020;5:169\u201379. https:\/\/doi.org\/10.1016\/j.jacbts.2019.11.007.","journal-title":"JACC Basic Transl Sci"},{"key":"260_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207\u201358. https:\/\/doi.org\/10.1152\/physrev.00015.2009.","journal-title":"Physiol Rev"},{"key":"260_CR35","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: A thrifty substrate hypothesis. Diabetes Care. 2016;39:1108\u201314. https:\/\/doi.org\/10.2337\/dc16-0330.","journal-title":"Diabetes Care"},{"key":"260_CR36","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.3390\/ijms21217833","volume":"21","author":"YC Hou","year":"2020","unstructured":"Hou YC, Zheng CM, Yen TH, Lu KC. Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int J Mol Sci. 2020;21:7833. https:\/\/doi.org\/10.3390\/ijms21217833.","journal-title":"Int J Mol Sci"},{"key":"260_CR37","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122:624\u201338. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311586.","journal-title":"Circ Res"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00260-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T23:01:56Z","timestamp":1766098916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-025-00260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["260"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00260-6","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be performed in accordance with the Declaration of Helsinki and the Japanese Clinical Trials Act (Japanese Clinical Trial Registry approval number: jRCTs041210022), and informed consent will be obtained from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TO is affiliated with a department sponsored by Medtronic Japan Co., Ltd. TO received research grants from Pfizer Global Supply Japan Inc., Alnylam Japan K.K., and Alexion Pharmaceuticals, Inc., and lecture fees from Pfizer Global Supply Japan Inc., Novartis Pharma Co., Ltd., Astra Zeneca Co. Ltd., and Boehringer Ingelheim Japan Co., Ltd., which were not connected to this work. TN received a research grant from Mitsubishi Tanabe Pharma Corp, Roche Diagnostics K.K. and honoraria from Bayer Yakuhin, Ltd., Kyowa Kirin Co., Ltd., Viatris Pharmaceuticals Japan Inc., Nippon Boehringer Ingelheim Co., Ltd., Bristol-Myers Squibb K.K. TA received honoraria from Daiichi Sankyo Co., Ltd., Boehringer Ingelheim Japan Co., Ltd., Bayer Pharmaceutical Co., Ltd., Astra Zeneca Co. Ltd., Byer and Novartis Pharma Co., Ltd., and clinical research grant from Abott Medical Japan LLC., Otsuka Pharmaceutical Co. Ltd., Japan Lifeline Co., Ltd., Boston Scientific Co. Ltd., Boehringer Ingelheim Japan Co., Ltd., and Daiichi Sankyo Co., Ltd., and scholarship funds from Biotronik Japan Co., Ltd., Medtronic Japan Co., Ltd., Win International Co., Ltd., Medical System Network Co., Ltd., and Hokuyaku Takeyama Holdings, Inc., Terumo Co., Ltd. The other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}